The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2019 | Relapsed myeloma treatment: what’s ahead?
Meral Beksac, MD, of Ankara University, Ankara, Turkey, discusses the options for treating relapsed multiple myeloma (MM), including second generation proteasome inhibitors, IMiDs and monoclonal antibodies. Furthermore, Dr Beskac talks about the exciting future of treatments using molecular and precision medicine by identifying genes involved in response to MM. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
